Aromatase (CYP19) Polymorphism Between AI-responsive and AI-resistant Breast Cancer in Korea — CYP19

Polymorphism Clinical Trial

Official title:
Aromatase (CYP19) Polymorphism Between AI-responsive and AI-resistant Breast Cancer in Korea

Status Suspended

Clinical Trial Summary

Aromatase(CYP19)inhibitor is one of the major antihormonal drug for breast cancer in postmenopausal women. The variation of CYP19 may affect the effect of aromatase inhibitor. However, the incidence of variation of CYP19 in Korea has not known. Therefore, the investigators want to know the incidence of variation of CYP19 and to assess the effect of these variations of CYP19 to aromatase inhibitor users.

Clinical Trial Description

n/a

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01137136
Study type	Observational
Source	Samsung Medical Center
Contact
Status	Suspended
Phase	N/A
Start date	June 2010
Completion date	December 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03859882` - Protocol PERCAF 2018	N/A
Recruiting	`NCT03114826` - Study of the Impact of VEGF Polymorphism on the Development of Renal Carcinoma in Renal Transplant Patients	N/A
Completed	`NCT02743468` - Cytochrome P450 Epoxygenase Pathway Regulation of Macrophage Function
Completed	`NCT01708083` - Polymorphids an mRNA Expression in Obese Genes	N/A
Completed	`NCT01239914` - CathOlic Medical Center percutAneous Coronary inTervention Registry (COACT)
Completed	`NCT03855774` - Polymorphisms, Caffeine and Sleep Disorders	N/A
Recruiting	`NCT04565834` - Effect of Genetic Alterations in Key Genes in the Kynurenine Pathway on Suicidal Behavior
Not yet recruiting	`NCT03262363` - Curcumin on NFE2L2 Gene Expression, Antioxidant Capacity and Renal Function According to rs35652124 in Diabetic Nephropathy	Phase 2/Phase 3